March 20th 2023
Gary J. Schiller, MD, discusses the treatment for blastic plasmacytoid dendritic cell neoplasm and what clinicians need to look out for when evaluating these rare occurrences.
Pemmaraju Discusses Data, Approvals, and Challenges for Hematologic MalignanciesMarch 2nd 2023
During a live Twitter Spaces event hosted by Targeted Oncology, Naveen Pemmaraju, MD, explained key abstracts from ASH 2022 and how these data have influenced recent approvals in the hematology field.
Biology Informs Treatment Options for Steroid-Refractory Chronic GVHDFebruary 22nd 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed biologic phases of chronic graft-vs-host disease and which therapies are available for patients who do not respond to steroids.
Acceptable Safety Seen With Orca-Q in the Haplo SCT Setting for High-risk Hematologic MalignanciesFebruary 17th 2023
At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.
Cytopenias Did Not Affect Ruxolitinib Efficacy in REACH2 Post Hoc AnalysisFebruary 17th 2023
Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.
Ruxolitinib for GVHD in Patients < 2 Years Old Shows Variable PharmacokineticsFebruary 17th 2023
According to findings presented at the 2023 Transplantation & Cellular Therapy Meetings, experts did not identify clear correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib in patients with graft-vs-host-disease.
Early Trial of Orca-T Produces 100% OS Rate in Hematologic Malignancies and 7/8 Mismatched DonorsFebruary 17th 2023
In 8 patients with various hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors, Orca-T led to a 100% survival rate.
Early Treatment With Ruxolitinib Induces High Response Rates in SR-aGVHDFebruary 17th 2023
The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.
Real-World Data Shows Survival Improvement for aGVHD After Ruxolitinib IntroductionFebruary 17th 2023
Looking at a retrospective analysis of data from a single-center, the use of ruxolitinib decreased non-relapse mortality and improved overall survival for patients with steroid-refractory acute graft-vs-host-disease.
Primary Analysis of Phase 3 TRANSFORM Study Confirms Benefit of Liso-Cel in LBCLFebruary 7th 2023
In an interview with Targeted Oncology, Jeremy Abramson, MD, discussed findings of the phase 3 TRANSFORM study which were presented at the 2022 American Society of Hematology Annual Meeting.
FDA Green Lights Fast Track Designation to Tamibarotene for Higher-Risk MDSJanuary 27th 2023
Tamibarotene has received fast track designation from the FDA for use in patients with higher-risk myelodysplastic syndrome. The agent is being further evaluated in the phase 3 SELECT MDS-1 trial.
Review of Myelodysplastic Syndromes Aids Experts in Diagnosing and Treating PatientsDecember 27th 2022
In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.
Safah Explores Disease Features and Treatment Options for Chronic GVHDDecember 20th 2022
During a Targeted Oncology case-based roundtable event, Hana Safah, MD, discussed chronic graft-vs-host disease in terms of diagnosis, phases, risk assessment, and treatment options.
Treating Elderly Patients With ALL Remains a Challenge for OncologistsDecember 16th 2022
In an interview with Targeted Oncology, Marlise Luskin, MD, MSCE, discussed the challenges of treating adult and elderly patients with acute lymphoblastic leukemia and where new research in the space is headed.
Crovalimab Treatment in the COMMODORE Trial Meets Coprimary End PointsDecember 11th 2022
COMMODORE study results are positive for its two primary end points of stable hemolysis control and transfusion avoidance in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab.